Bank of New York Mellon Corp lifted its position in shares of Pulse Biosciences Inc (NASDAQ:PLSE) by 113.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 55,567 shares of the company’s stock after acquiring an additional 29,588 shares during the period. Bank of New York Mellon Corp’s holdings in Pulse Biosciences were worth $1,034,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nationwide Fund Advisors acquired a new stake in shares of Pulse Biosciences during the second quarter worth $177,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Pulse Biosciences during the second quarter worth $250,000. California Public Employees Retirement System acquired a new stake in shares of Pulse Biosciences during the second quarter worth $297,000. OxFORD Asset Management LLP acquired a new stake in shares of Pulse Biosciences during the second quarter worth $310,000. Finally, Rhumbline Advisers acquired a new stake in shares of Pulse Biosciences during the second quarter worth $325,000. 9.30% of the stock is owned by institutional investors.

A number of equities research analysts have recently weighed in on the company. BidaskClub raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Friday, December 29th. ValuEngine raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 31st.

In related news, Director Maky Zanganeh purchased 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was acquired at an average price of $23.07 per share, with a total value of $92,280.00. Following the completion of the purchase, the director now directly owns 332,500 shares in the company, valued at $7,670,775. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Robert W. Duggan purchased 22,901 shares of the company’s stock in a transaction that occurred on Thursday, October 19th. The stock was bought at an average cost of $22.79 per share, with a total value of $521,913.79. Following the purchase, the insider now owns 5,820,513 shares of the company’s stock, valued at $132,649,491.27. The disclosure for this purchase can be found here. 6.70% of the stock is owned by insiders.

Shares of Pulse Biosciences Inc (PLSE) opened at $23.07 on Friday. Pulse Biosciences Inc has a twelve month low of $5.82 and a twelve month high of $39.50. The firm has a market capitalization of $381.08 and a price-to-earnings ratio of -16.48.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Tuesday, November 7th. The company reported ($0.52) earnings per share for the quarter.

ILLEGAL ACTIVITY WARNING: “Bank of New York Mellon Corp Boosts Stake in Pulse Biosciences Inc (PLSE)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-boosts-stake-in-pulse-biosciences-inc-plse/1805342.html.

About Pulse Biosciences

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences Inc (NASDAQ:PLSE).

Institutional Ownership by Quarter for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.